This study is a long-term evaluation of the total pregnancy potential of cohorts of fresh and cryopreserved sibling embryos from in-vitro fertilization (TVF) cycles stimulated with either the gonadotrophin-releasing hormone analogue buserelin (BUS) (long protocol) or clomiphene citrate (CC) both in combination with human menopausal gonadotrophin (HMG). Therefore a retrospective analysis was performed on patients who entered the FVT programme between January 1986 and July 1987 and who had triple embryo transfer in the collection cycle. Significantly more fertilized oocytes developed to good-quality embryos in the CC-HMG group (86.1%) than in the BUS-HMG group (80.8%). Transfer of the three morphologically best-looking embryos was performed on day 2 post-insemination in 106 CC-HMG and 80 BUS-HMG cycles. Supernumerary embryos were cultured for a further 24 h and multicellular embryos with up to 20% of fragments were frozen slowly with 1.5 M dimethylsulphoxide on day 3 post-insemination (162 embryos in CC-HMG cycles, 102 embryos in BUS-HMG cycles). Outcome was measured by embryo survival rate, embryo implantation rate and delivery rate in fresh and frozen embryo transfers. Delivery rates were 31.3 and 21.7% per fresh embryo transfer in BUS-HMG and CC-HMG cycles respectively. Fresh embryo implantation rates were significantly higher in collection cycles stimulated with BUS-HMG (17.9%) than in cycles stimulated with CC-HMG (113%). Implantation rates were significantly enhanced in embryos transferred in excess of one in cycles leading to pregnancy, perhaps indicative of higher embryo quality in BUS-HMG cycles. Almost all cryopreserved embryos have by now been thawed, so the contribution of frozen embryos to overall pregnancy rates can be evaluated. Overall morphological survival rates of frozen-thawed embryos were similar for 140 embryos from CC-HMG cycles (50%) and 100 embryos from BUS-HMG cycles (46%). The percentage of fully intact embryos was, however, significantly lower in the BUS-HMG group (19%) than in the CC-HMG group (39.5%). Delivery rates were significantly lower following 30 transfers of frozen-thawed embryos from BUS-HMG-stimulated cycles (3.3%) than following 42 transfers of frozen-thawed embryos from CC-HMG cycles (19.1%). Embryo implantation rates were © European Society for Human Reproduction and Embryology lower for frozen-thawed embryos from BUS-HMG cycles (23%) than from CC-HMG cycles (12.7%). Here we demonstrate that ovarian stimulation with the long protocol BUS-HMG instead of the CC-HMG protocol led to higher embryo implantation rates in collection cycles but to lower intact embryo survival rates and to lower embryo implantation rates for frozen sibling embryos. Despite the lower implantation rates with frozen embryos originating from the BUS-HMG protocol, there was no significant difference between total delivery rate per transfer from cycles stimulated with CC-HMG (30.2%) compared with BUS-HMG (33.8%).
Introduction
Today the use of desensitizing gonadotrophin-releasing hormone analogues (GnRHa) in combination with gonadotrophins has become almost universal for ovarian stimulation in invitro fertilization (TVF) cycles as a substitute for ovarian stimulation with clomiphene citrate (CC) and gonadotrophins. The question as to the impact of these desensitizing fertility drugs on embryo quality and embryo implantation potential still remains. To be able to formulate an answer to this question, at least for our centre, we looked at data from the period when both GnRHa and non-GnRHa cycles were being earned out. We deliberately chose to analyse the data in the long term so that results on the implantation potential of the full cohort of fresh and frozen embryos were available. This attitude prevented us from having to speculate on prospective pregnancy rates of substantial numbers of embryos that are still kept in frozen storage.
The start of our study coincided with the worldwide introduction of GnRHa in combination with gonadotrophins for the treatment of human infertility. The combination of a desensitizing GnRHa with the administration of exogenous gonadotrophic hormones allowed an increase in the success rates of IVF in patients with premature luteinizing hormone (LH) surges, in poor responders or in patients with polycystic ovaries (PCO) or endometnosis. Similarly, the use of GnRHa as a first-line treatment enabled better planning of cycles and significantly decreased the cancellation rate so that the efficacy of ovarian stimulation therapy for IVF was improved overall. Several prospective randomized studies (Neveu et al, 1987; Macnamee et al, 1989; Abdalla et al., 1990 , Ron-El et al., 1991 Dhont et al, 1995) found that not only the efficacy of treatment was improved in terms of fewer cancellations, but that the pregnancy rate per cycle was significantly higher in the group of patients receiving ovarian stimulation with the GnRHa buserelin (BUS) or goserelin in combination with human menopausal gonadotrophin (HMG) or follicle stimulating hormone (FSH) than in the group of patients receiving ovarian stimulation with the non-GnRHa CC in combination with HMG or FSH. Other authors (Chetkowski et al., 1989; Antoine et al., 1990) comparing leuprolide acetate-HMG and decapeptyl-HMG with HMG alone found higher, although not significantly so, pregnancy rates in cycles with GnRHa treatment than in cycles without. The higher pregnancy rates were explained by a significant increase in the numbers of oocytes collected and, hence, embryos from which to choose for transfer and/or by an increased receptivity of the endometrium (Neveu etai, 1987; Smitz etal, 1987 Smitz etal, , 1989 Rutherford etal, 1988; Serafini et aL, 1988; Macnamee et aL, 1989; Testart et aL, 1989b; Hassiakos et aL, 1990; Tur-Kaspa et al, 1990; Dhont et aL, 1995) . Higher pregnancy rates after GnRHa and gonadotrophin treatment were not confirmed by Kingsland et al. (1990) , Kubik et al. (1990) and Maroulis et al. (1991) , who reported that GnRHa-treated cycles gave pregnancy rates similar to those for non-GnRHa-treated cycles.
The reported benefit of GnRHa treatment has to be evaluated, however, in terms of not only the outcome of fresh embryo transfers but also frozen-thawed embryo transfers. Here too there have been conflicting reports Testart et al. (1989a,b) reported that the absolute number of embryos was increased after GnRHa treatment but that the proportion of good-quality embryos was reduced, so that the supernumerary embryos for freezing were of worse quality than in non-GnRHa cycles. These authors considered that this decreased quality of embryos for cry ©preservation was a major determinant factor in the lower embryo implantation rate of frozen-thawed embryos from GnRHa-treated cycles. Van Steirteghem et al. (1989) , Van den Abbeel et al. (1990) and Smitz et al. (1992) reported that the post-thaw survival rate and the implantation rates of both pronuclear and multicellular frozen-thawed embryos were significantly lower when they originated from GnRHastimulated rather than CC-HMG-stimulated gamete intraFallopian transfer (GIFT) cycles. Interestingly, Gu6rin et al. (1989) and Lornage et al. (1990) made a distinction between long and short GnRHa stimulation protocols and found that the decreased embryo survival and implantation rates after freezing were related, in particular, to the long protocol combining buserelin and HMG. Similarly, the ongoing pregnancy rate per transfer seemed to be better when the short GnRHa-HMG protocol was used rather than either the long GnRHa-HMG protocol or even the CC-HMG protocol. Other experienced groups (Macnamee et aL, 1989; Antoine et al., 1990; Mandelbaum, 1990; Fugger et al., 1991) have not reported a decrease in embryo quality, embryo survival rates or pregnancy rates for frozen-thawed embryos derived from GnRHa cycles versus non-agonist cycles.
Here it is our aim to document the experience of GnRHa treatment versus CC-HMG treatment in our centre by reporting data on the period when stimulation with CC-HMG was gradually being replaced by stimulation with BUS-HMG. To make the comparison between BUS-HMG-and CC-HMG-2098 stimulated cycles as strict as possible, we considered the outcome of triple embryo transfer with freezing of the supernumerary embryos. We have evaluated these data 8 years after the introduction period because only by now have 98 and 86% of the embryos from the BUS-HMG and CC-HMG cycles been thawed respectively. Because we considered that the pregnancy rate in the BUS-HMG group can no longer be changed significantly by the two embryos remaining in storage and as there is little chance that the other 20 embryos in the CC group will be thawed in the near future, we decided to end our analysis in September 1994 when, in addition, we also changed our thawing policy in a way which would, in any case, render the data from before and after the switch incomparable.
Materials and methods

Patients
From January 1986 to July 1987, 186 IVF cycles with triple embryo transfer were included in this study Two stimulation protocols were used simultaneously during this period In 106 of these 186 cycles CC (Serophene*; Serono, Geneve, Switzerland) in combination with HMG (Pergonal; Serono; or Humegon; Organon, Oss, The Netherlands) was used for ovanan stimulation CC was given at a dose of 100 mg/day from days 3 to 7 of the cycle. HMG administration was started on day 7 of the cycle at a dose of 150 IU/day. Depending on the serum oestradiol concentrations and ultrasound findings, the dose of HMG was then adjusted if necessary. In the remaining 80 of the 186 cycles, the GnRH agonist buserelin acetate (Suprefact®, Hoechst, Frankfurt, Germany) was administered intranasally at a daily dose of 6X 100 |ig. Following a 3 week desensitization phase with buserelin, HMG was given at a dose of 150 IU/day for 4 days For the following days the dose of HMG was adapted according to the response to the treatment. In both types of ovarian stimulation protocol, ovulation was induced with 10 000 IU human chorionic gonadotrophin (HCG; Profasi®, Serono; or Pregnyl®; Organon) when the serum oestradiol concentration was >1000 ng/1 and when at least three follicles had reached a diameter of 17 mm as revealed by ultrasound.
Embryos
Oocyte retrieval was performed by laparoscopy or ultrasound-guided pick-up under local anaesthesia. The collected oocytes were inseminated and cultured as described previously (Staessen et al, 1989) . Fertilization was assessed by screening for the presence of two distinct pronuclei 16-18 h post-insemination, and embryo cleavage was assessed another 24-28 h later. Embryos were classified according to the stage of development and morphological quality. The morphological score used four types of embryo of decreasing quality: type 1, embryos with equally-sized blastomeres and no anucleate fragments, type 2, embryos with unequally-sized blastomeres and no anucleate fragments or embryos with up to 20% of their volume filled with anucleate fragments; type 3, embryos with >20% and *50% of their volume filled with anucleate fragments; and type 4, embryos with >50% of their volume filled with anucleate fragments. The three morphologically best embryos were selected for transfer in the collection cycle on day 2 post-inseminanon The supernumerary embryos were cultured further until day 3 post-insemination. Cleaved embryos with <20% fragmentation (type 1 or 2) were then allocated to a cryopreservation protocol with dimethylsulphoxide (DMSO).
Slow freezing of human multicellular embryos with 1.5 M DMSO
The slow-freezing protocol with 1.5 M DMSO (British Drug House Ltd, Poole, UK) was earned out as described by . The freezing medium consisted of HEPES-buffered Earle's medium with 10% human maternal serum and DMSO. Embryos were equilibrated in 0.75 M DMSO at room temperature for 10 min. They were then transferred to glass ampoules (Wheaton 6201-B36; Polylab, Belgium) containing 400 ul of a 1 5 M DMSO solution; these ampoules were kept at 4°C on crushed ice for another 10 nun. After transfer to a biological freezer (Planer R202, Planer Products, Sunbury-on-Thames, UK) preset at 4°C, embryos were cooled further to -6°C at a rate of -2°C/min. Seeding was then induced manually by touching the ampoule with a liquid nitrogen (LN 2 )-cooled pincet. The temperature was held at -6°C for 10 nun. Further freezing was performed at a cooling rate of -0.3°C/min down to -80°C, at which temperature the ampoule was immersed in LN 2 . Thawing was performed by removing an ampoule from the LN 2 and putting it immediately on crushed ice for 15 min. Then the ampoule was emptied and the embryo transferred to a solution containing 1 M DMSO at room temperature for 10 min Gradual dilution was continued in solutions of 0 750 and 0.375 M DMSO for 10 min each at room temperature Thereafter, embryos were nnsed twice in HEPES-buffered Earle's medium and twice in embryo culture medium They were finally transferred to a 25 uJ droplet in a culture dish (Staessen et al, 1989) . Embryos were cultured for 4-8 h before replacement Slow freezing of human pronuclear-stage embryos with 1.5 M 1,2-propanediol The slow-freezing protocol with 1 5 M 1,2-propanediol (PROH; Fluka, Buchs, Switzerland) was earned out as described by Van Steirteghem et al (1987) . Embryos were equilibrated in HEPESbuffered Earle's medium with 10% human maternal serum and 1 5 M PROH plus 0 1 M sucrose at room temperature for 15 min. They were then transferred to glass ampoules that were put into a biological freezer Embryos were cooled from room temperature (22°C) to -6°C at a rate of -2°C7min Following seeding, further slow cooling was performed at a rate of -0.3°C/min down to -30°C. Thawing was performed rapidly by putting an ampoule from the LN 2 immediately into a water bath at room temperature. The ampoule was emptied and the embryo transferred to a solution containing 1.0 M sucrose at room temperature for 10 min Thereafter, embryos were nnsed twice in HEPES-buffered Earle's medium and twice in embryo culture medium and were finally transferred to a 25 (xl droplet in a culture dish (Staessen et al, 1989) Embryos were cultured for 24-30 h before replacement
Embryo survival after thawing
An evaluation of embryo survival after thawing was performed by microscopic inspection of the morphology of thawed embryos under both a stereomicroscope (magnification X50) and an inverted microscope (magnification X400). Embryos were defined as surviving morphologically when the zona pellucida was not damaged and when at least 50% of the initial number of blastomeres were intact after thawing and showed a smooth cell membrane and a clear cytoplasm without clumping
Frozen embryo transfer
One or two surviving embryos were transferred per frozen embryo transfer cycle Frozen-thawed embryos were transferred during natural or shghdy stimulated ovanan cycles. If the patient had normal ovulatory function then embryos were transferred in the natural cycle. If the patient had no normal ovulatory function the transfer cycle was stimulated by the administration of CC alone or in combination with HMG Transfer cycles were monitored in the pen-ovulatory period by daily measurement of the serum concentration of 17(3-oestradiol, LH and progesterone by a direct radioimmunoassay procedure from day 8 onwards. If the LH surge occurred and progesterone concentrations were 5*1.5 mg/1, multicellular embryos were thawed on day 4 following the day of the LH surge. If progesterone concentrations were <1.5 mg/1, the thawing was postponed for 1 day. Almost all frozen embryo transfers were performed in natural cycles. From day 10 after the LH nse onwards, the concentration of HCG in the serum was measured Initial pregnancy was defined as a significant increase in serum HCG concentrations in at least two measurements within 10 days of embryo transfer Clinical pregnancy was defined as the observation of a gestational sac by means of echographic screening at 7 weeks of pregnancy. The delivery rate was defined as the number of deliveries compared with the number of transfers performed. The embryo implantation rate was defined as the number of fetal sacs per number of embryos transferred The childbirth rate was defined as the number of live births as a proportion of the number of embryos transferred.
Statistics
Means were compared using Student's r-test Survival, pregnancy and delivery rates as well as embryo implantation and childbirth rates were compared using the % 2 test The level of significance was set at P =£ 0.05
Results
Overview of all CC-HMG and BUS-HMGIVF cycles between January 1986 and July 1987
From 235 CC-HMG oocyte retrievals, 1435 oocyte-cumulus complexes were retrieved, representing a mean of 6.1 oocytes per retrieval (Table I) . Of these 1435 oocyte-cumulus complexes, 867 (60.4%) showed two pronuclei after insemination. In all, 40 two-pronuclear oocytes were frozen, and the remaining majority of 827 two-pronuclear oocytes were cultured. Of these cultured two-pronuclear oocytes, 555 (67.1%) cleaved to type 1 and 2 embryos. A total of 184 transfers were carried out with 443 embryos, among which were 386 type 1 and 2 embryos, plus 57 type 3 embryos. The pregnancy rate was 25% per transfer and the delivery rate 17.4%. The embryo implantation rate was 10.6% and the childbirth rate was 8.8% per embryo transferred.
In 151 BUS-HMG oocyte retrievals, 1204 oocyte-cumulus complexes were retrieved, representing a mean of 8.0 oocytes per retrieval Of these, 726 (60.1%) showed two pronuclei after insemination In all, 69 two-pronuclear oocytes were frozen, and the remaining majority of 657 two-pronuclear oocytes were cultured. Of these cultured two-pronuclear oocytes, 371 (56.5%) cleaved to type 1 and 2 embryos, significantly lower than in the CC-HMG group (P = 0.0001, X 2 = 17.22). A total of 123 transfers were performed with 301 embryos, among which were 259 type 1 and 2 embryos, plus 42 type 3 embryos The pregnancy rate was 31.7% per transfer and the delivery rate 24.4%. The embryo implantation rate was 16.6% and the childbirth rate was 14.3% per embryo transferred, both of which were significantly higher than in the CC-HMG group (P = 0.02, % 2 = 5.18 and P = 0.03, X 2 = 4.95 respectively). In the CC-HMG group, 41.3% of all oocyte retrievals gave nse to embryo freezing, and a total of 169 supernumerary type 1 and 2 embryos were frozen. Of the triple embryo transfers, 66% gave rise to embryo freezing, and 162 of the total of 169 supernumerary type 1 and 2 embryos were frozen in these triple embryo transfer cycles. In the BUS-HMG group, 42.4% of all oocyte retrievals gave rise to embryo freezing, and 112 supernumerary type 1 and 2 embryos were frozen. Of the triple embryo transfers, 63.8% gave rise to freezing and 102 of the total of 112 supernumerary type 1 and 2 embryos were frozen in these triple embryo transfer cycles. Further data in this paper refer to these cycles with triple embryo transfer. Table II documents the patient and stimulation characteristics for 106 CC-HMG and 80 BUS-HMG treatment cycles with triple embryo transfer. The indications for infertility and the age of the patients were not significantly different across the two groups of ovarian stimulation. A significantly higher number of ampoules of HMG (29.7 ± 3.1) was given in the BUS-HMG group than in the CC-HMG group (12.3 ± 5.0).
Patient and embryo characteristics in CC-HMG and BUS-HMG IVF cycles with a triple embryo transfer
In the 106 CC-HMG-stimulated cycles 749 oocytes were retrieved, corresponding to 7.2 oocytes per cycle (Table IH) . Of these, 578 were assessed as fertilized by the presence of two distinct pronuclei (fertilization rate 77.2%). In all, 16 twopronuclear oocytes were frozen and 562 were cultured for 24 h. Of the 562 cultured, 551 (98.0%) cleaved further. This corresponds to a mean number of 5.2 cleaved embryos per cycle. The cleavage rate to type 1 and 2 embryos was 86.1%.
Of the 551 cleaved embryos, 318 (57.7%) were chosen for fresh triple embryo transfer and 233 (42.3%) were supernumerary. Of these 233 supernumerary embryos, 34 (14.6%) were of excellent quality and showed no anucleate fragments, 128 (54.9%) were of good quality and showed maximally up to 20% of fragments while 71 (30.5%) were of poor quality and showed fragments over >20% of their volume. The poor quality embryos were not considered to be suitable for freezing; hence, 162 of the 233 supernumerary embryos (69.5%) were finally frozen. Until now, 140 of these 162 embryos (86.4%) have been thawed for transfer, two embryos thawed for research and 20 embryos are still in storage for possible patient use.
In the 80 BUS-HMG-stimulated cycles 664 oocytes were retrieved, corresponding to 8.4 oocytes per cycle. Of these, 491 were assessed as fertilized by the presence of two distinct pronuclei (fertilization rate 73.9%). A total of 38 twopronuclear oocytes were frozen and 453 were cultured for 24 h. Of these, 401 (88.5%) cleaved further. This corresponds to a mean number of 5.0 cleaved embryos per cycle, which is not significantly different from the corresponding value in the CC-HMG group (5.2). The cleavage rate to type 1 and 2 embryos was 80.8%. Both the overall cleavage rate and the •/» = 0 0001.x 2 = 37 41 b P = 0 03, x 2 = 4 84 cleavage rate to type 1 and 2 embryos were significantly lower than the corresponding rates in the CC-HMG cycles (P = 0 0001, X 2 = 37.41 and P = 0.03, % 2 = 4.84 respectively). Of the 401 embryos cleaved, 240 (59.9%) were chosen for fresh triple embryo transfer and 161 (41.1%) were supernumerary. Of these 161 supernumerary embryos, 12 (7 4%) were of excellent quality and showed no anucleate fragments, 90 (55.9%) were of good quality and showed up to 20% of fragments, while 59 (36.7%) were of poor quality and showed fragments over >20% of their volume. The poor quality embryos were not considered to be suitable for freezing; hence, 102 of the 161 supernumerary embryos (63.4%) were finally frozen. To date, 100 of these 102 frozen embryos (98.0%) have been thawed. The remaining two embryos are still in storage for possible patient use.
Outcome of fresh triple embryo transfer
In the CC-HMG group 318 embryos were transferred in 106 triple embryo transfers (Table IV) . The majority of embryos transferred (92 8%) were of good to excellent quality (types 1 and 2) The outcome in terms of positive HCG gave a pregnancy rate of 33.0% per cycle. Five pregnancies were lost as preclinical abortions; thus 30 clinical pregnancies were established, corresponding to a clinical pregnancy rate of 28.3% per cycle. In these 30 clinical pregnancies, 36 amniotic sacs were diagnosed by ultrasound assessment, giving an embryo implantation rate of 11.3% per embryo transferred. Of the 30 clinical pregnancies, 23 resulted in a delivery, corresponding to a delivery rate of 21.7% per transfer (23/ 106). In all, 28 children have been bom. Therefore the childbirth rate per embryo transferred reached a value of 8.8% (28/318). The multiple pregnancy rate (twin rate) per transfer was 20.0% (six twins out of 30 clinical pregnancies).
In the BUS-HMG-stimulated group 240 embryos were transferred in 80 triple embryo transfers. Of these 240 embryos, 87 9% were of good to excellent quality, and this percentage was comparable with that for the CC-HMG group. A positive HCG measurement was obtained after 32 transfers, so that the positive HCG rate was 40 0% per cycle. amniotic sacs were diagnosed by ultrasound assessment, giving an embryo implantation rate of 17.9% per embryo transferred, significantly higher than the 11.3% embryo implantation rate in CC-HMG cycles (P = 0.04; x 2 = 4.37). Of the 28 clinical pregnancies, 25 resulted in a delivery, corresponding to a delivery rate of 31.3% per cycle. In all, 38 children have been bom. The childbirth rate per embryo transferred was 15.8%, which is significantly higher than the 8.8% embryo implantation rate in CC-HMG cycles (P < 0.02; y} = 5.82). The multiple pregnancy rate per transfer was 39.3% (nine twins and two triplets out of 28 clinical pregnancies).
To gain an idea of the interaction between embryo quality and uterine receptivity, we studied the implantation rate of embryos transferred in excess of one in cycles where a pregnancy was established (Table V) . In 30 clinical pregnancies in the CC-HMG group 60 embryos were transferred in excess of one, 10% of which implanted. In 28 clinical pregnancies in the BUS-HMG group 56 embryos were transferred in excess of one, 26.8% of which implanted. The implantation rate of embryos in excess of one was significantly higher in the BUS-HMG group than in the CC-HMG group (P = 0.004, X 2 = 4.43).
Outcome of frozen embryo transfer
In the CC-HMG-stimulated group the overall morphological embryo survival rate was 50% (70/140; In the BUS-HMG-stimulated group the overall morphological survival rate was 46% (46/100), similar to that for embryos from CC-HMG cycles. Of the 100 thawed embryos, 19 (19.0%) were fully intact after thawing and 27 (27.0%) showed =£50% blastomere loss. Significantly fewer embryos from the BUS-HMG group than from the CC-HMG group were fully intact after thawing (P = 0 0006; x 2 = 17.30, df = 3). Significantly more embryos from the BUS-HMG group (16/100) than from the CC-HMG group (1/140) showed zona pellucida damage after thawing {P = 0.0001; X 2 = 18.45). Of the 46 surviving embryos, 44 were finally transferred in 30 transfer procedures. This gave an average number of 1.5 embryos per transfer. Of these 30 embryo transfers, six positive HCG measurements were registered, corresponding to an initial pregnancy rate of 20.0% per transfer. Of these six singleton pregnancies, one evolved well and has led to the delivery of a child. The implantation rate per embryo transferred was 2.3%, which was on the borderline of being significantly lower than in the CC-HMG group. The delivery rate was 3.33% per transfer, which is significantly lower than for frozen embryo transfers from CC-stimulated cycles (F = 0.05; x 2 = 3.95). The childbirth rate per embryo transferred was 2.3%, and 1.0% per embryo thawed; these are borderline significantly lower than the corresponding values for frozen embryo transfers from CC-HMG-stimulated cycles (/> = 0.056; x 2 = 3.66 per embryo transferred and P = 0.058; x 2 = 3.59 per embryo thawed).
Contribution of pregnancies from frozen embryo transfers to the overall pregnancy rate
In Table VII an overview is given of all pregnancies ensuing from fresh and frozen embryo transfers originating from 106 CC-HMG IVF cycles and 80 BUS-HMG IVF cycles with triple embryo transfer. The pregnancies ensuing from the frozen two-pronuclear embryos have also been included. Today there is general agreement that the use of GnRHa in combination with HMG for ovarian stimulation permits a strict scheduling of oocyte retrievals and decreases significantly the cancellation rate for oocyte retrievals, representing clear advantages for the daily activities of centres for reproductive medicine. Most investigators also agree that there is a significant increase in the number of oocytes retrieved and in the number of embryos available for transfer (Neveu et al., 1987; Serafini et aL, 1988; Smitz et aL, 1992; Dhont et aL, 1995) . Recently it has been confirmed, in a prospective randomized study on unselected patients, that the virtual absence of cancellation of the cycle and the increased number of oocytes are the main determinants of the higher efficacy of GnRHa/ HMG treatment m terms of pregnancy rate per cycle (Dhont et aL, 1995) . However, the impact of GnRHa/HMG treatment on the outcome of frozen embryo transfers still seems to be producing highly conflicting results. Here we report our experience of the long-term evaluation of both fresh and frozen embryo transfers for GnRHa-HMG versus CC-HMG ovarian cycles. On the one hand, the clinical embryo implantation rate was higher in collection cycles stimulated with BUS-HMG than in cycles stimulated with CC-HMG. On the other hand, this picture was reversed in frozen embryo transfers Here, the clinical embryo implantation rate was lower following the transfer of frozen-thawed embryos derived from BUS-HMG cycles than from CC-HMG cycles. However, we show that even though the outcome of frozen embryo transfers from GnRHa cycles may be less good in terms of implantation and delivery rates, there is still an advantage to GnRHa cycles over CC-HMG cycles when the outcomes of fresh and frozen cycles are taken together.
There was no difference in patient profile in terms of age and indication for infertility between the CC-HMG and BUS-HMG groups. Similarly, the number of embryos transferred was comparable between both groups, consistently being three for the fresh cycle because only triple transfers were considered and being ±1.5 for the frozen embryo transfers.
In the fresh embryo transfer cycle there was no significant difference in the delivery rate per transfer between BUS-HMG and CC-HMG cycles, but the implantation rate of embryos was significantly higher in the BUS-HMG group. To make a finer distinction between the influence of embryo quality and uterine receptivity on implantation, the implantation rate of embryos in excess of one was investigated in pregnant cycles where uterine receptivity was established. It was shown that the number of implantations in excess of one was significantly higher in the BUS-HMG group. This may be indicative of higher embryo quality in BUS-HMG-stimulated ovarian cycles.
After frozen embryo transfer the implantation rate of embryos from the BUS-HMG group was, however, significantly lower. A lowered implantation rate may be a result of deficient embryo quality or suboptimal uterine receptivity. As almost all transfers in this study were performed in natural cycles, the lowered implantation rate may indeed correlate with the fact that embryos from the BUS-HMG group were of inferior quality after thawing. The overall morphological 2104 survival rate based on the proportion of embryos with intact blastomeres was not different between the BUS-HMG and CC-HMG groups, but more embryos were fully intact after thawing in the CC-HMG group than in the BUS-HMG group. Nevertheless, there was no significant difference in embryo quality before freezing. It is possible that the inferior quality of embryos in the BUS-HMG group is proved only by the freezing procedure. Another intriguing observation in this sense was the higher incidence of zona pellucida damage (16%) among the thawed embryos of the BUS-HMG group. As zona pellucida damage can induce additional blastomere damage, this may be an interacting factor leading to a further decreased potential of embryos to remain fully intact after thawing.
Our results on the outcome of frozen embryo transfers in the BUS-HMG group are in agreement with the findings of Testart et aL (1989a,b) and Gu6rin et al. (1989) , who also reported an adverse effect from BUS-HMG stimulation on the survival and implantation rates of frozen-thawed embryos. Testart et al. (1989a,b) reported that the overall survival rate at thawing was 18.0% for embryos from GnRHa cycles versus 46.3% for embryos from cycles without GnRHa treatment. Among the transferred frozen-thawed embryos, 3-4% implanted when derived from a GnRHa cycle versus 12-13% of those derived from a non-GnRHa cycle. These results are similar to our results, where 2.3% implanted when derived from a GnRHa cycle versus 12.7% of those derived from a nonGnRHa cycle. Testart et al. (1989a,b) used the cryoprotectant PROH for freezing, and only top-quality embryos with no irregular blastomeres or cytoplasmic exudates were frozen.
An interesting finding comes from the study by Guerin et al. (1989) , who compared the outcome of CC-HMG stimulation with both long and short BUS-HMG stimulations. More embryos were available for cryopreservation using the long protocol, but the survival and implantation rates were lower than for the short protocol or for the non-GnRHa protocol. Surprisingly, the short GnRHa protocol gave the highest implantation rates for frozen-thawed embryos, at 16.1 versus 8.6% for the long protocol.
Our results are in disagreement with those published by Mandelbaum (1990) , Demoulin et al. (1991) , Fugger et al. (1991) and Oehninger et al. (1992) , who did not find any adverse effect from GnRHa on the survival and implantation rates of frozen-thawed embryos. When looking more carefully into the results of these groups, pronuclear-stage embryos (Demoulin et al., 1991; Fugger et al., 1991; Oehninger et al., 1992) or very good-quality embryos without fragments were frozen (Mandelbaum, 1990) .
It is clear that the issue of the effect of GnRHa on the quality of cryopreserved multicellular embryos is not yet settled. However, as many centres now cryopreserve embryos at the two-pronuclear stage, it is important to know whether, if there is an effect of GnRHa, it would affect the pronuclear stage. In our cryopreservation programme two-pronuclear embryos became frozen on two occasions. First, in cycles with many oocytes where many fertilized, it happened that pronucleate embryos became frozen. The number of cases (see Table VII ) was too low to allow us to perform a statistical analysis, but the outcome was worse for the group of frozenthawed two-pronuclear embryos originating from BUS-HMGstimulated cycles (1/10 deliveries/embryo transfer; 1/13 children/embryo transferred) compared with CC-HMG cycles (1/4 deliveries/embryo transfer; 1/5 children/embryo transferred) The second occasion on which two-pronuclear embryos became frozen in our settings was the occurrence of GIFT cycles in which two or three oocytes were replaced in the Fallopian tube and the remaining oocytes were fertilized in vitro. Some of the fertilized two-pronuclear embryos were frozen as such and the remainder was cultured further; the developing multicellular embryos also became frozen (Smitz et al, 1992) . The analysis of GIFT cycles provides the opportunity to study the developmental potential of an unselected group of oocytes. In all, 216 CC-HMG and 97 BUS-HMG cycles were studied. In the fresh GIFT cycle there was no difference in clinical pregnancy rate between both stimulation protocols. From the supernumerary fertilized zygotes, fewer developed to good-quality embryos in the BUS-HMG cycles (37.0%) than in the CC-HMG cycles (50 4%) {P < 0.005). Of the frozen two-pronuclear embryos, fewer survived the thawing in the BUS-HMG group (41.3 versus 62.3%) (P < 0.005) and a lower pregnancy rate per transfer ensued (0/15 versus 6/40 pregnancies/transfer). In addition, of the frozen multicellular embryos, fewer survived the thawing in the BUS-HMG group (30.2 versus 53.3%) and a lower pregnancy rate per transfer ensued (1/11 versus 10/50 pregnancies/transfer). The overall implantation rate of supernumerary frozen-thawed embryos after GIFT was 0.7% for BUS-HMG cycles versus 6.8% for CC-HMG cycles. Thus, in our experience, the embryo survival and embryo implantation rates were always worse in GnRHa-HMG GIFT cycles. The reduced survival and implantation rates for frozen-thawed embryos originating from down-regulated cycles, be it two-pronuclear or multicellular embryos, may therefore perhaps be due to a shared factor which might be the 2-fold greater administration of HMG in BUS-HMG cycles compared with CC-HMG cycles. In the same context, it has been suggested by Pelbcer et al. (1989) that the retrieval of higher numbers of oocytes in patients treated with a combination of GnRHa and gonadotrophins may be correlated with oocytes of lower quality.
The relevance of our study lies in the fact that the outcome of cryopreservation has been evaluated sufficiently long after the time of freezing so that practically all frozen embryos have been thawed and the potential of the whole cohort of fresh and frozen embryos can be evaluated. A concern may be that the results obtained from these data for 1986-87 are no longer representative of the present situation because there may have been an improvement in the quality of handling and the quality of embryos over the years. Indeed there are certain parameters that have improved over the years, such as the number of retrievals per started cycle and the number of oocytes per retrieval. These improvements are probably due exclusively to the use of agonists. Other parameters, however, such as the percentage of transfers per retrieval and the quality of embryos expressed as the number of further cleaved zygotes, have remained fairly constant over the years from 1986 to date. Moreover, the pregnancy rate per transfer in the cryopreservation programme has been declining over the years, so that the data obtained in the years 1986-87 cannot be suspected to be artificially low. In two further studies (Camus et al, 1991; Van der Elst et al, 1995) we confirmed the findings from the present report, that after the transfer of frozen-thawed embryos from BUS-HMG cycles we never again reached the level of the delivery rate after transfer of frozen-thawed embryos from CC-HMG cycles.
In the meantime, GnRHa treatment has been introduced worldwide as a mode of ovanan stimulation. In our hands, GnRHa stimulation has a positive effect on implantation in the fresh cycle and a negative effect on embryo quality and implantation in the frozen cycle. As this adverse effect from GnRHa stimulation on embryo cryopreservation is not experienced by all teams that use GnRHa for ovarian stimulation, we must perhaps study the data more carefully to detect the factors that may be responsible for the less favourable outcome of frozen embryo transfers. If GnRHa stimulation really has a detrimental effect on embryo quality after freezing, such that the implantation rate is reduced, then cell biological studies will be needed to reveal whether pituitary desensitization followed by ovanan stimulation recruits other types of oocyte in a way that gives the resulting embryos a smaller chance of overcoming freezing stress. In the meantime, it may be possible to increase the outcome of the frozen cycle by tailoring the stimulation protocols or by making a far more stringent selection in terms of the morphological quality of the frozenthawed multicellular embryos to be transferred. This study has allowed us also to illustrate that the price for increased success in the fresh cycle may have to be paid in the frozen cycle. The final lesson may be that we ought to be more selective and be led by the cnterion of quality rather than quantity.
